MedTrace Logo

EValuation of REsidual Platelet REactivity After Acute Coronary Syndrome (ST+/ST-) in HIV

NCT02380391 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 260

Last updated 2015-03-05

No results posted yet for this study

Summary

Elevated on-treatment platelet reactivity is an independent risk factor of major adverse cardiovascular events following percutaneous coronary intervention or ACS. People living with HIV patients have a higher risk of recurrent events after ACS than people without HIV.

The investigators hypothesized that this increased risk is driven by higher platelet reactivity.

Using a nested case-control study design, HIV-infected and HIV-uninfected patients with a first episode of Acute Coronary Syndrome (ACS) treated with percutaneous coronary intervention were matched for age, sex, known diabetes mellitus and anti-platelet therapy.

The primary end-point was the residual platelet reactivity (RPA) on dual antiplatelet therapy assessed by light transmission aggregometry (LTA, 20µM ADP).

The study was conducted in a two large public university hospitals in central Paris, France.

Conditions

  • Acute Coronary Syndrome
  • HIV

Sponsors & Collaborators

  • Groupe Hospitalier Pitie-Salpetriere

    collaborator OTHER

  • Saint Antoine University Hospital

    lead OTHER

Principal Investigators

  • Franck Boccara, MD, PhD · Saint Antoine University Hospital

  • Ariel Cohen, MD, PhD · Saint Antoine University Hospital

  • Jean Philippe Collet, MD, PhD · ACTION Study Group, Unité de Recherche Clinique-Hôpital Lariboisière (APHP) and Université Paris 6, INSERM, Paris, France

  • Johanne Silvain, MD, PhD · ACTION Study Group, Unité de Recherche Clinique-Hôpital Lariboisière (APHP) and Université Paris 6, INSERM, Paris, France

  • Gilles Montalescot, MD, PhD · ACTION Study Group, Unité de Recherche Clinique-Hôpital Lariboisière (APHP) and Université Paris 6, INSERM, Paris, France

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02380391 on ClinicalTrials.gov